SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharma trades higher on the BSE

30 Oct 2017 Evaluate

Torrent Pharmaceuticals is currently trading at Rs. 1276.90, up by 11.50 points or 0.91% from its previous closing of Rs. 1265.40 on the BSE.

The scrip opened at Rs. 1250.15 and has touched a high and low of Rs. 1282.45 and Rs. 1250.15 respectively. So far 3769 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1572.10 on 31-Mar-2017 and a 52 week low of Rs. 1143.50 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 1411.45 and Rs. 1244.00 respectively. The current market cap of the company is Rs. 21593.67 crore.

The promoters holding in the company stood at 71.25%, while institutions and non-institutions held 18.52% and 10.24% respectively.

Torrent Pharma is reportedly in advanced discussion to buy Unichem Lab’s domestic business. The company’s domestic business generates revenue of around Rs 900 crore. For the domestic assets, the company is likely to offer Rs 3,250 crore. The deal may be announced next week if the talks fructify.

Currently, Unichem Lab is ranked 25th in the domestic market. The company’s operations are 57 percent of its sales and within the domestic business, chronic care business comprises 59 percent of the sales.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharma Share Price

4186.35 7.50 (0.18%)
20-Apr-2026 11:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×